Status:
COMPLETED
Open Label Continuation Study in Moderate to Severe Psoriasis
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Moderate to Severe Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.
Eligibility Criteria
Inclusion
- Having participated in a preceding ABT-874 clinical trial for ABT-874
- Subject has a clinical diagnosis of moderate to severe plaque psoriasis
Exclusion
- Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
2301 Patients enrolled
Trial Details
Trial ID
NCT00626002
Start Date
February 1 2008
End Date
October 1 2011
Last Update
January 30 2013
Active Locations (152)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 7496
Birmingham, Alabama, United States, 35205
2
Site Reference ID/Investigator# 8438
Birmingham, Alabama, United States, 35233
3
Site Reference ID/Investigator# 7522
Huntsville, Alabama, United States, 35801
4
Site Reference ID/Investigator# 7774
Scottsdale, Arizona, United States, 85251